QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
NYSE:ENZ

Enzo Biochem - ENZ Stock Forecast, Price & News

$1.38
-0.05 (-3.17%)
(As of 02/6/2023 02:02 PM ET)
Add
Compare
Today's Range
$1.38
▼
$1.47
50-Day Range
$1.16
▼
$2.00
52-Week Range
$1.11
▼
$3.51
Volume
24,867 shs
Average Volume
56,303 shs
Market Capitalization
$67.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Enzo Biochem MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Enzo Biochem in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$213,520 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

981st out of 1,027 stocks

Medical Laboratories Industry

24th out of 25 stocks

See Top Rated MarketRank™ Stocks Here
ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

February 1, 2023 | americanbankingnews.com
Enzo Biochem, Inc. (NYSE:ENZ) Major Shareholder Buys $16,520.00 in Stock
February 1, 2023 | americanbankingnews.com
Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com
February 6, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 29, 2023 | marketwatch.com
Non-Radioactive Nucleic Acid Labeling Product Market Size, Sales, CAGR And Competition Data from 2023 To 2028 with Top Countries Data
January 23, 2023 | nasdaq.com
James Wolf Ups Stake in Enzo, May Seek Board Seat
January 18, 2023 | reuters.com
ENZ.DF - | Stock Price & Latest News | Reuters
January 16, 2023 | benzinga.com
Biomarkers Market is expected to grow from USD 66.6 billion in 2022 to USD 183.42 billion by 2030 : GreyViews
December 17, 2022 | marketwatch.com
Clinical Reference Laboratory Services Market 2023-2028 : Leading Growth Drivers, Emerging Audience, Segments, Industry Sales, Profits & Analysis
February 6, 2023 | Investing Trends (Ad)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
December 16, 2022 | finance.yahoo.com
Enzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Call Transcript
December 13, 2022 | seekingalpha.com
Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript
December 13, 2022 | finanznachrichten.de
Enzo Biochem, Inc.: Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update
December 13, 2022 | marketwatch.com
Oligomycin Market 2023 : Size (value & volume) by Company, Key Regions, Type, and Application 2028
December 13, 2022 | marketwatch.com
Quizartinib Market 2023 : Industry Analysis, Opportunities, Technology, Top Players and Growth Forecast 2028
December 12, 2022 | finance.yahoo.com
Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update
December 7, 2022 | finance.yahoo.com
Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th
November 18, 2022 | finance.yahoo.com
As Enzo Biochem, Inc. (NYSE:ENZ) drops to US$100m market cap, insiders might rethink their US$3.1m stock purchase earlier this year
November 8, 2022 | finance.yahoo.com
Enzo Biochem, Inc. Announces Date of Annual Shareholders’ Meeting
October 24, 2022 | nasdaq.com
Shareholders in Enzo Biochem (NYSE:ENZ) are in the red if they invested five years ago
October 20, 2022 | finance.yahoo.com
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
October 17, 2022 | finance.yahoo.com
The past five years for Enzo Biochem (NYSE:ENZ) investors has not been profitable
October 15, 2022 | finanznachrichten.de
Enzo Biochem, Inc.: Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
October 14, 2022 | finance.yahoo.com
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
October 10, 2022 | benzinga.com
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
October 10, 2022 | finance.yahoo.com
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
October 6, 2022 | finance.yahoo.com
Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York
September 26, 2022 | finance.yahoo.com
Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
12/12/2022
Today
2/06/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
7/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ENZ
CUSIP
N/A
CIK
316253
Web
www.enzo.com
Phone
(212) 583-0100
Fax
212-679-7999
Employees
451
Year Founded
1976

Profitability

EPS (Most Recent Fiscal Year)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,260,000.00
Net Margins
-26.89%
Pretax Margin
-26.89%
Return on Equity
-38.65%
Return on Assets
-22.26%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
1.84
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$107.07 million
Price / Sales
0.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.12 per share
Price / Book
1.24

Miscellaneous

Outstanding Shares
48,720,000
Free Float
41,168,000
Market Cap
$67.46 million
Optionable
Optionable
Beta
0.87

Social Links


Key Executives

  • Hamid Erfanian
    Chief Executive Officer & Director
  • Kara Cannon
    Chief Operating Officer
  • Patricia Eckert
    Chief Financial Officer
  • Dieter Schapfel
    Chief Medical Director
  • Matthew Kupferberg
    Secretary & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?

Enzo Biochem's stock was trading at $1.43 on January 1st, 2023. Since then, ENZ shares have increased by 0.0% and is now trading at $1.43.
View the best growth stocks for 2023 here.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 344,100 shares, an increase of 9.1% from the December 15th total of 315,300 shares. Based on an average daily volume of 66,600 shares, the days-to-cover ratio is presently 5.2 days. Currently, 1.0% of the company's shares are short sold.
View Enzo Biochem's Short Interest.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ENZ earnings forecast.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings results on Monday, December, 12th. The medical research company reported ($0.18) EPS for the quarter. The medical research company earned $18.28 million during the quarter. Enzo Biochem had a negative net margin of 26.89% and a negative trailing twelve-month return on equity of 38.65%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $1.43.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $69.67 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 451 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 2/6/2023 by MarketBeat.com Staff